SecBot SecBot
PRESS-RELEASE ·Filed Apr 14, 2026

SYRE

Spyre Therapeutics, Inc.
NEUTRAL
Impact 6/10
Horizonimmediate Processed7mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight • Neutral

Traders should monitor for potential near-term dilution impact; however, the capital raise strengthens Spyre’s cash position for clinical development. The stock may react negatively short-term due to dilution, but long-term impact depends on pipeline execution.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$68.99
T+0 close · Apr 14, 2026 · via day close
Latest settled
+41.67%
T+60 · $97.74
Vs SPY
+33.54%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 15 $68.99entry
  2. T+1 · 7mo ago +1.03%α +0.78% · $69.70
  3. T+5 · 7mo ago +5.81%α +4.17% · $73.00
  4. T+20 · 6mo ago +8.77%α +2.73% · $75.04
  5. T+60 · 4mo ago +41.67%α +33.54% · $97.74
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Spyre Therapeutics priced an underwritten public offering of 6.5 million shares at $62.00 per share, raising approximately $403.0 million in gross proceeds, with an additional $60.5 million option for underwriters to purchase more shares. The offering is expected to close on April 16, 2026, subject to customary conditions.

Key Financial Metrics

Deal Value
$403.0M

Key Facts

  • Spyre Therapeutics is offering 6,500,000 shares of common stock at $62.00 per share.
  • Gross proceeds are expected to be approximately $403.0 million, before underwriting discounts and expenses.
  • Underwriters have a 30-day option to purchase up to an additional $60.5 million worth of shares.
  • The offering is expected to close on or about April 16, 2026.
  • Jefferies, Goldman Sachs, Evercore ISI, and Guggenheim Securities are joint book-running managers.

Financial Impact

$403.0 million raised, with potential for $463.5 million total if the overallotment is exercised

dilutioncashequity

Risk Factors

  • Dilution to existing shareholders from the issuance of new shares
  • Market conditions and investor sentiment toward biotech offerings may affect pricing and demand

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3274098

Track record

36 reports on SYRE

Performance horizon

8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 15 of 21 went positive at some point.

Filters
  1. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  2. Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
  3. Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  4. Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  5. Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  6. Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  7. Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  8. Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  9. Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  10. Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
Showing 10 of 36

US Market Status

Market Closed · Opens in 8h 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 14, 2026